Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Status:
Withdrawn
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is an open label study to evaluate the efficacy of intravitreal aflibercept injection
2mg in patients with a persistent FVPED despite at least 6 consecutive injections with
ranibizumab 0.5 mg.